Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

97% response rate for Rituxan + CHOP in small pilot trial in intermediate- or high-grade NHL

May 21, 1998

Favorable preliminary phase I/II trials results reported at ASCO for Titan's cancer vaccines

May 21, 1998

GVAX induces immune responses in prostate cancer patients

May 21, 1998

Herceptin: promising phase III results reported at ASCO

May 20, 1998

Neurocrine Biosciences initiates clinical-stage development of IL-4 fusion toxin

May 19, 1998

Leuvectin proceeds to phase II for renal cell carcinoma

May 19, 1998

Antigenics receives patent protection for HSP-based cancer immunotherapy

May 15, 1998

Bexxar: encouraging interim phase III data reported

May 14, 1998

DAB389IL-7, a novel fusion protein for the specific elimination of IL-7 receptor-positive cells

May 12, 1998

Patient enrollment begins for U.S. trial of Maxamine in malignant melanoma

May 11, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...